Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria

Area of Science:

• Nephrology
• Immunology
• Rheumatology

Background:

• Severe proteinuria is a significant complication in Systemic Lupus Erythematosus (SLE) patients, often indicating lupus glomerulonephritis.
• Membranous nephropathy, particularly WHO class V, is a common cause of proteinuria in SLE.
• Existing immunosuppressive treatments may not be sufficient for all patients with persistent severe proteinuria.

Purpose of the Study:

• To evaluate the efficacy of Mycophenolate mofetil (MMF) in reducing proteinuria in SLE patients with persistent severe proteinuria.
• To assess the impact of MMF on renal function, serum albumin levels, and corticosteroid dosage.
• To explore MMF as a potential treatment for lupus glomerulonephritis, including cases resistant to other therapies.

Main Methods:

• A prospective study involving 20 consecutive SLE patients with persistent severe proteinuria and/or proteinuric flare.
• Patients received MMF therapy for 18 months, with doses ranging from 1.5 g to 3 g daily.
• Outcomes measured included proteinuria reduction (partial: >=50% decrease, complete: <0.3 g/24h), serum albumin, and prednisone dosage.

Main Results:

• All 20 patients (100%) achieved at least a 50% reduction in proteinuria within 8.2 months of MMF therapy.
• Mean 24-hour proteinuria significantly decreased (3.47 to 1.33 g), serum albumin increased (3.2 to 3.7 mg/dl), and prednisone dose reduced (33.7 to 18.6 mg/day).
• Complete response (normal proteinuria) was observed in 11 patients (55%) within 12.2 months, with significant improvements in all measured parameters.

Conclusions:

• Mycophenolate mofetil (MMF) demonstrates significant efficacy in reducing severe persistent proteinuria in lupus glomerulonephritis.
• MMF therapy led to improved renal function markers and allowed for a reduction in corticosteroid requirements.
• This study suggests MMF is a viable and effective treatment option for lupus nephritis-associated proteinuria, even in patients unresponsive to other immunosuppressants.